University of Groningen
Genomic medicine in inflammatory bowel disease
Voskuil, Michiel
DOI:
10.33612/diss.136307453
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Voskuil, M. (2020). Genomic medicine in inflammatory bowel disease. University of Groningen. https://doi.org/10.33612/diss.136307453
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
548072-L-sub03-st-Voskuil 548072-L-sub03-st-Voskuil 548072-L-sub03-st-Voskuil 548072-L-sub03-st-Voskuil Processed on: 3-9-2020 Processed on: 3-9-2020 Processed on: 3-9-2020
Processed on: 3-9-2020 PDF page: 1PDF page: 1PDF page: 1PDF page: 1
Crohn’s disease susceptibility genes may contribute to pathogenesis in a cell-type-specific context. (this thesis)
The composite genetic risk of Crohn’s disease is associated with Crohn’s disease behaviour. (this thesis)
The composite genetic risk of ulcerative colitis is associated with Crohn’s disease location. (this thesis)
Genetic variation in NUDT15 and TPMT, and thiopurine weight-adjusted dose are all independent predictors of thiopurine-induced myelosuppression in patients with inflammatory bowel disease. (this thesis)
Rare genetic variation contributes to clinical heterogeneity. (this thesis)
Pre-treatment genetic testing should be considered prior to initiation of thiopurine therapy. (this thesis)
Genetic risk alone will never be able to capture all clinical heterogeneity of patients with inflammatory bowel disease. (this thesis)
Molecular studies of individual intestinal cells will be essential for understanding the gut immune system and identifying potential therapeutic targets.
Genetic risk is dynamic and depends on changing factors such as environmental exposures.
Je hoeft niet altijd de beste te zijn, zolang je maar de eerste bent.
1 2 3 4 5 6 7 8 9 10
Michiel D. Voskuil, Groningen 2020 Stellingen behorend bij het proefschrift
